Solvonis Therapeutics PLC (SVNS)

ORD GBP0.001

Sell: 0.21p|Buy: 0.22p|Change: 0.00 (-0.47%)

Open

0.22p

Previous close

0.212p

Trade high

0.227p

Volume

46,535,529

Year high

0.40p

Year low

0.13p

Dividend yield

–

Market capitalisation

£14.36 mn

P/E ratio

1.35

ISIN

GB00BMD1Z199

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA SIPPand can be used with Dividend reinvestment

Share price

Performance 05/06/2026

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
Solvonis Therapeutics PLC	- 0.47
More...

Company profile

Solvonis Therapeutics PLC focuses on the development of therapeutic solutions. The company is engaged in the development of novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders focusing on addiction and psychiatry. The products in company's pipeline include SVN-001, SVN-002, SVN-015. SVN-114, and others.

Sector

Industrials

News

Recent trades

Date	Time	Price	Quantity	Value (£)
05/06/2026	04:35:15	0.211	1,579,432	3,332.60
05/06/2026	04:07:13	0.22	287	0.63
05/06/2026	03:50:57	0.2188	2,000,000	4,376.00
05/06/2026	03:36:26	0.22	9,045	19.90
05/06/2026	03:36:26	0.22	13,728	30.20

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.